Tarsus Pharmaceuticals, Inc. · NASDAQ:TARS

Tarsus Pharmaceuticals — Q3 2026 Earnings Presentation

13 slides from Tarsus Pharmaceuticals's earnings presentation, Nov 3, 2026

  1. Slide 1: Building the Future of Eye Care

    Building the Future of Eye Care Q3 2026 Financial Results November 2026 Vivian, an XDEMVY patient.

  2. Slide 2: Today's Speakers

    World-Class Leadership Team With Proven Track Record of Success: Today’s Speakers Bobby Azamian, MD, PhD Neera Clase Jeff Farrow Sesha Neervannan, PhD Elizabeth Yeu, MD CEO & Chairman Chief Commercial Officer Chief Financial & Strategy Officer Chief Operating Officer Chief Medical Officer 2 | © Tars

  3. Slide 3: Forward-looking Statements

    Forward-looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. These statements include statements regarding the potential commercial success and growth of XDEMVY in Demodex blepharitis, including 2026 updated financial guidance, market size, a

  4. Slide 4: Delivering Continued Value Creation And Patient Impact In Eye Care

    Delivering Continued Value Creation And Patient Impact In Eye Care *$2B+ Has acquired $715- $730M iRenix $451M $180M Expanding Into Retina 5 Potential Medicines in 5 Years ‘24A ‘25A ‘26E ‘27+ 1M+ bottles, $1B+ in cumulative sales Two new investigational programs: One of the most and a record $194M+

  5. Slide 5: XDEMVY Growth Engine Driving $2B+ Annual Peak Sales Potential

    XDEMVY® Growth Engine Driving $2B+ $2B+ Annual Peak Sales Potential Peak Sales Potential Deepening Growing High-Impact DTC Evidence Utilization Retreatment Campaign Generation ECPs prescribing XDEMVY 5+ ~20% of weekly High-value actions up 75% in 11 new AAOpt abstracts give times per week rose nearl

  6. Slide 6: Q3 Was One of Our Most Effective and Efficient DTC Quarters to Date

    Q3 Was One of Our Most Effective and Efficient DTC Quarters to Date Patients are asking for XDEMVY by name What ECPs told us at AAOpt Higher Rx Conversion +$5M DTC Investment 75% Website visitors are converting to office visits, diagnoses and prescriptions at a higher rate than last year Full-year D

  7. Slide 7: Compelling New Evidence Gives ECPs More Reasons to Screen, Diagnose and Treat

    Compelling New Evidence Gives ECPs More Reasons to Screen, Diagnose and Treat Demodex Blepharitis Clinician satisfaction with retreatment (N=100) DB prevalence in chalazion/hordeolum patients Patients improved at 9 months XDEMVY vs. other management 91% Satisfied or very 98% 65% 73% satisfied Itchy

  8. Slide 8: Just Scratching the Surface on Demodex Blepharitis, A Large, Untapped Addressable Market

    Just Scratching the Surface on Demodex Blepharitis, A Large, Untapped Addressable Market ~25M Americans with DB1 • Weekly refills grew to ~20%3 • DTC is driving new patients impacted by Demodex blepharitis into care • ECPs making diagnosis and treatment a consistent part of practice 9M+ Seeking trea

  9. Slide 9: Strong Growth in Q3 2026

    Strong Growth in Q3 2026 $194.6mm ~$310mm XDEMVY Net Sales1 Cash & Cash Equivalents3 Q3 2026 +63.9% XDEMVY Fueling Investment in YoY Net Sales Growth2 Innovation Note: U.S. dollars in millions unless otherwise noted. 1. Net sales for the three months ending September 30, 2026. 2. Net sales growth re

  10. Slide 10: Updated 2026 Financial Guidance

    Updated 2026 Financial Guidance XDEMVY Gross SG&A R&D Acquired Net Sales Margin Expense Expense IPR&D $715–$730M ~93% $605–$620M $140–$155M ~$632M Incl. $45–$50M Incl. $20–$25M $551M Alkeus stock comp stock comp $81M iRenix $685–$705M previous reiterate $545–$565M previous $190–$210M previous Q3 202

  11. Slide 11: Advancing One of the Most Differentiated Pipelines in Eye Care

    Advancing One of the Most Differentiated Pipelines in Eye Care Positioned to Deliver Multiple Potential Blockbusters Indication Phase 1 Phase 2 Phase 3 Approved Demodex blepharitis (U.S.) Approved Demodex blepharitis (China)1 Approved ALK-001 Stargardt disease Phase 3, topline data expected in 2029

  12. Slide 12: Delivering Continued Value Creation And Patient Impact In Eye Care

    Delivering Continued Value Creation And Patient Impact In Eye Care *$2B+ Has acquired $715- $730M iRenix $451M $180M Expanding Into Retina 5 Potential Medicines in 5 Years ‘24A ‘25A ‘26E ‘27+ 1M+ bottles, $1B+ in cumulative sales Two new investigational programs: One of the most and a record $194M+

  13. Slide 13: Thank You!

    Thank You! 13 | © Tarsus Pharmaceuticals | For Investor Purposes Only Diamond, an XDEMVY patient.

Tarsus Pharmaceuticals — Q3 2026 Earnings Presentation on 6ix